Deliver Your News to the World

CybeRelease: (OTC: IVME) Announces New Patent Filing


(CybeRelease, August 17, 2006) - Lake Harmony, PA - IVMD Inc. (OTC BB: IVME), a novel medical device company, today announced the filing of an important patent in its suite of intellectual Property.

Following on from the filing of its first immunoassay patent last year, IVMD has developed a low cost, unambiguous, yes/no assay format. The technology uses IVMD’s expertise in its core technology, together with its low-cost design and manufacturing methodology that was developed for its first groundbreaking product.

The immunoassay format is self powered, sensitive, and can be produced at a cost level that will make it completive in the mass market e.g. over the counter pregnancy and ovulation testing, as well as a screening tool for diseases such as HIV or substances such as drugs or alcohol. As such it could spin off a number of applications in large, global markets.

John Fuller, CEO Operations, said, “The development of the technique and filing of a new patent shows IVMD’s commitment to building a strong portfolio of IP which can be commercially exploited to add shareholder value. Throughout the development program IVMD worked closely with its marketing team to define the true market requirements, and the product has been targeted strongly at being competitive in the Over the Counter space. We are currently in discussions with a number of blue chip diagnostics companies to commercialize the product in various sectors.”

The Immunoassay Market in the USA alone was worth $7Bn per annum in 2002.

For a Free Newsletter and more information, go to

To read the complete release, go to

CybeRelease Gainers are Itron, Inc. (Nasdaq: ITRI), Panera Bread Company (Nasdaq: PNRA), NetLogic Microsystems, Inc. (Nasdaq: NETL), Medis Technologies Ltd. (Nasdaq: MDTL), Guitar Center, Inc. (Nasdaq: GTRC), VistaPrint Limited (Nasdaq: VPRT), PolyMedica Corporation (Nasdaq: PLMD) and IPC Holdings, Limited (Nasdaq: IPCR).

CybeRelease Decliners are Magellan Health Services, Inc. (Nasdaq: MGLN), New River Pharmaceuticals Inc. (Nasdaq: NRPH), Gen-Probe Incorporated (Nasdaq: GPRO), Casey’s General Stores, Inc. (Nasdaq: CASY), ArthroCare Corporation (Nasdaq: ARTC), Medallion Financial Corp. (Nasdaq: TAXI), NMT Medical Inc. (Nasdaq: NMTI) and Casella Waste Systems, Inc. (Nasdaq: CWST).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.